Thrombolex, Inc.

Compelling results of the RESCUE II Clinical Trial were recently presented during TCT 2024. Dr. Christian Bichard shared data from patients with acute intermediate-risk pulmonary embolism (PE) treated with the BASHIR™ Endovascular Catheter. Conducted at Temple University by Drs. Riyaz Bashir and Vladimir Lakhter, the study highlights the effectiveness of single-session pharmacomechanical lysis (PML) without the need for post-procedural thrombolytic infusion. #Thrombolex https://lnkd.in/eNUhhr37

Join Dr. Christian Bichardin the Innovation Theater tomorrow (10/28) morning at 9:34am for an in-depth review of the compelling results of the RESCUE II Study in treating acute intermediate-risk Pulmonary Embolism (PE). The RESCUE II Study, conducted at Temple University by Drs. Riyaz Bashir and Vladimir Lakhter, demonstrates the remarkable efficacy of the BASHIR™ Endovascular Catheter in providing rapid, on-table pharmacomechanical lysis (PML) without the need for prolonged post-procedural thrombolytic infusion. Thrombolex.com #Thrombolex

The BASHIR™ Plus Family of Endovascular Catheters enables the restoration of blood flow for peripheral vessels with extensive thrombus burden. The mechanical expansion and optimized delivery of r-tPA through the basket and along the length of the catheter offer an individualized approach to treating peripheral venous disease. Thrombolex.com #Thrombolex

Join Thrombolex at Booth 813 at TCT 2024 to explore how our innovative endovascular catheters can revolutionize pulmonary embolism treatment in a single session. Thrombolex.com #Thrombolex

Visit Thrombolex at Booth 813 during the TCT Conference in Washington, D.C. and be sure to attend the Innovations in Endovascular Therapies Session on 10/28 where Dr. Christian Bichard will present the compelling results from the RESCUE II Study. Thrombolex.com #Thrombolex

The BASHIR™ Endovascular Catheter offers safe and effective treatment for pulmonary embolism (PE). The Catheter's innovative design delivers targeted low-dose lytics to optimize clot resolution in a single session, minimizing patient risk and maximizing patient outcomes. Thrombolex.com #Thrombolex

Thrombolex announces the first two patients enrolled in the RAPID-PE Clinical Study evaluating an advanced on-the-table protocol for the treatment of Pulmonary Embolism (PE). The RAPID-PE study is a single-arm, multi-center post market study evaluating the safety and effectiveness of on-the-table pharmacomechanical lysis (PML) without post-procedural thrombolytic infusion using the BASHIR™ Endovascular Catheter. Learn more at https://lnkd.in/g3TzNqyg Thrombolex.com #Thrombolex

Safety is essential when treating arterial and venous thromboembolic disease (A&VTE). The BASHIR™ Endovascular Catheter’s advanced design and optimized thrombolytic delivery are clinically proven to reduce complications and improve patient outcomes. Thrombolex.com #Thrombolex

Take the complexity out of treating pulmonary embolism. Optimize PE treatment using the BASHIR™ .035 Family of Endovascular Catheters. Thrombolex.com #Thrombolex

On Indigenous Peoples' Day, we honor the rich cultures, histories, and contributions of Indigenous communities Thrombolex.com #Thrombolex